The high strength easily biodegradable pollutants (represented by CODE) are strong inhibitors of terephthalic acid (TA) anaerobic biodegradation. At the same time, TA can inhibit easily biodegradable pollutants removal under anaerobic conditions to a limited extent. This mutual inhibition could happen and cause a low removal efficiency of both TA and CODE, when the effluent from TA workshops containing TA and easily biodegradable pollutants are treated by a single anaerobic reactor system. Based upon the treatment kinetics analysis of both TA degradation and CODE removal, a two-stage up-flow anaerobic sludge blanket and up-flow fixed film reactor(UASB-UAFF) system for dealing with this kind of wastewater was developed and run successfully at laboratory scale. An UASB reactor with the methanogenic consortium as the first stage removes the easily biodegradable pollutants(CODE). An UAFF reactor as the second stage is mainly in charge of TA degradation. At a CODE loading of 15.3 g/(L.d) and a TA loading of 1.4 g/(L.d), HRT 18.5 h, the CODE and TA removal rate of the system reached 89.2% and 71.6%, respectively.
Download full-text PDF |
Source |
---|
Alzheimers Dement
December 2024
Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Alzheimer's disease (AD) exhibits substantial heterogeneity in its disease trajectory. A subset of AD patients with unmatched cognitive decline/tauopathy severity has not been well studied. We identified such atypical subgroups in post-mortem AD brain studies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Exeter, Exeter, Devon, United Kingdom.
Alzheimer's disease (AD) is a multi-factorial and complex disease, with the risk of developing disease still largely unknown despite numerous genetic and epidemiological studies over recent years. Several genetic and modifiable lifestyle risk factors are known to contribute to disease etiology, and epigenetic mechanisms are suggested to also contribute my mediating their interaction. It is now ten years since we published the first cross-tissue epigenome-wide association study (EWAS) of DNA methylation in AD post-mortem brain samples, with subsequent studies nominating robust and reproducible alterations in genes such as ANK1, HOXA3 and RHBDF2.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
McGill University, Montreal, QC, Canada.
Background: Intracellular accumulation of tau tangles in the brain is one of the most prominent manifestations of Alzheimer's disease (AD). Progression thereof across the AD stages has specific temporal and spatial patterns, wherein time is informative of space and vice versa. Here we introduce a novel method, Manifold Component Analysis (MCA), to represent tangle accumulation in 2D, reflecting the spatial aspect of tau propagation stages to further relate it to the temporal aspect thereof.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurocognitive Unit, Division of Neurology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Episodic memory change is among the earliest symptoms of Alzheimer's disease (AD). Accumulation of neurofibrillary tangles in limbic regions serves as a key indicator of the initial tau abnormality. This study aimed to investigate the correlations between episodic memory change and quantitative tau deposition specifically in Braak stage 3-4 Limbic regions among participants with mild cognitive impairment (MCI) and mild dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
A critical need exists to find simpler approaches for early detection of Alzheimer disease (AD) and related dementias. These approaches must increase access to preventative interventions and treatments, both pharmacological and non-pharmacological, for people in preclinical and prodromal stages of disease. This need has been amplified by the emergence of disease modifying therapies (DMTs), which require biological confirmation of amyloid-ß positivity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!